Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -4.97% and Operating profit at -204.30% over the last 5 years
- NET SALES(9M) At CNY 586.59 MM has Grown at 20%
- NET PROFIT(HY) Higher at CNY -376.26 MM
- RAW MATERIAL COST(Y) Fallen by -314.45% (YoY)
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,088 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.38
-9.02%
0.79
Revenue and Profits:
Net Sales:
207 Million
(Quarterly Results - Jun 2025)
Net Profit:
-53 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.02%
0%
-7.02%
6 Months
-1.12%
0%
-1.12%
1 Year
-24.1%
0%
-24.1%
2 Years
-37.27%
0%
-37.27%
3 Years
-73.31%
0%
-73.31%
4 Years
-74.91%
0%
-74.91%
5 Years
-70.79%
0%
-70.79%
Zhejiang Orient Gene Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.97%
EBIT Growth (5y)
-204.30%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.16
Tax Ratio
3.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
471.21%
ROE (avg)
28.64%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.79
EV to EBIT
-3.30
EV to EBITDA
-4.59
EV to Capital Employed
0.66
EV to Sales
3.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-19.97%
ROE (Latest)
-9.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
206.50
189.00
9.26%
Operating Profit (PBDIT) excl Other Income
-46.90
-97.70
52.00%
Interest
1.60
3.80
-57.89%
Exceptional Items
6.50
-1.60
506.25%
Consolidate Net Profit
-53.30
-120.80
55.88%
Operating Profit Margin (Excl OI)
-486.30%
-800.10%
31.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.26% vs 17.98% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 55.88% vs 59.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
812.70
805.10
0.94%
Operating Profit (PBDIT) excl Other Income
-534.70
-474.70
-12.64%
Interest
20.60
19.30
6.74%
Exceptional Items
-70.90
-72.40
2.07%
Consolidate Net Profit
-568.80
-418.30
-35.98%
Operating Profit Margin (Excl OI)
-938.90%
-817.50%
-12.14%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.94% vs -90.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -35.98% vs -119.94% in Dec 2023
About Zhejiang Orient Gene Biotech Co., Ltd. 
Zhejiang Orient Gene Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






